QT prolongation is associated with systemic inflammatory response characterized by IL-6 upregulation and administration of IL-6 receptor blocking antibody (Tocilizumab) had yielded successful outcomes in decreasing the risk of QT interval related tachyarrhythmias including atrial fibrillation [31]. The gene discussed is IL6; the disease is atrial fibrillation.